Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 1,834 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo- C Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses

NCT07330674
View directory record Official record
Conditions
Age Related Macular Degeneration (ARMD), AMD - Age-Related Macular Degeneration
Interventions
ABF-101, Placebo
Drug
Lead sponsor
Aptabio Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 23, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults

NCT00708110
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1349572, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
18
States / cities
Bakersfield, California • Long Beach, California • Newport Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Oct 23, 2026, 10:12 AM EDT
Completed Phase 3 Interventional Results available

Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

NCT01709513
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Atorvastatin, Ezetimibe, Alirocumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
41
States / cities
Anaheim, California • Beverly Hills, California • Mission Viejo, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2020 · Synced Oct 23, 2026, 10:12 AM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Trenev Trio®/Healthy Trinity® for Recurrent Gastrointestinal Symptoms

NCT01444859
View directory record Official record
Conditions
Recurrent Gastrointestinal Symptoms
Interventions
Trenev Trio®/Healthy Trinity®, Placebo
Dietary Supplement
Lead sponsor
Sprim Advanced Life Sciences
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • West Lawn, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Oct 23, 2026, 10:12 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)

NCT05574010
View directory record Official record
Conditions
Celiac Disease
Interventions
Cohort 1 in Part A, Cohort 2 in Part A, Placebo: Group 1 in Part B and Part C, Group 2 in Part B and Part C, Group 3 in Part B and Part C, Group 4 in Part B and Part C
Drug · Other
Lead sponsor
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • Anaheim, California • St. Petersburg, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 23, 2026, 10:12 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

NCT02065570
View directory record Official record
Conditions
Crohn's Disease
Interventions
Adalimumab, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
48
States / cities
Birmingham, Alabama • Dothan, Alabama • La Jolla, California + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 23, 2026, 10:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Probiotics (L. Helveticus, B. Longum, and B. Bifidum) on Immune Function and Digestive Health

NCT01709825
View directory record Official record
Conditions
Healthy
Interventions
Probiotic- Bifidobacterium Bifidum, Sugar Pill, Probiotic- Lactobacillus helveticus, Probiotic- Bifidobacterium longum ss. Infantis R0033
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
583 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 29, 2015 · Synced Oct 23, 2026, 10:12 AM EDT
Completed Phase 2 Interventional

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

NCT01271790
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Tegobuvir (GS-9190), GS-9451, Pegasys®, Copegus®, Tegobuvir placebo, GS-9451 placebo
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
85
States / cities
Dothan, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 23, 2026, 10:12 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

NCT06782490
View directory record Official record
Conditions
Multiple Sclerosis Spasticity
Interventions
BMS-986368, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
16
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 10:12 AM EDT
Completed Phase 3 Interventional Results available

LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03049735
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroid
Interventions
Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
76
States / cities
Andalusia, Alabama • Mobile, Alabama • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 23, 2026, 10:12 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)

NCT03001076
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerosis, Statin Adverse Reaction
Interventions
Bempedoic acid, Ezetimibe, Placebo
Drug · Other
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Georgetown, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 23, 2026, 10:12 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity

NCT06857617
View directory record Official record
Conditions
Obesity and Overweight
Interventions
(Part C) MET097, (Part C) Placebo
Biological
Lead sponsor
Metsera, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Anaheim, California • Cypress, California • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 23, 2026, 10:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of IRL201104 in Healthy Volunteers

NCT05921591
View directory record Official record
Conditions
Healthy Volunteer
Interventions
IRL201104, Placebo
Drug
Lead sponsor
Revolo Biotherapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 23, 2026, 10:12 AM EDT
Not listed Phase 1 Interventional

Ursodiol in Huntington's Disease

NCT00514774
View directory record Official record
Conditions
Huntington Disease
Interventions
ursodiol, placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 5, 2009 · Synced Oct 23, 2026, 10:12 AM EDT
Completed Phase 2 Interventional

Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma

NCT01693315
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension, Eye Disease
Interventions
AMA0076, Placebo
Drug
Lead sponsor
Amakem, NV
Industry
Eligibility
30 Years to 85 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Artesia, California • Inglewood, California • Petaluma, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Oct 23, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)

NCT03679676
View directory record Official record
Conditions
Hypersensitivity, Food Allergy, Hypersensitivity, Food, Peanut Hypersensitivity, Peanut Allergy
Interventions
Omalizumab, Dupilumab, Placebo for Dupilumab, Placebo for Omalizumab
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 55 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 23, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

Tivantinib in Treating Patients With Metastatic Prostate Cancer

NCT01519414
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Laboratory Biomarker Analysis, Placebo, Tivantinib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
20
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 23, 2026, 10:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)

NCT01595516
View directory record Official record
Conditions
Prehypertension, Hypertension
Interventions
Nebivolol, Metoprolol, Placebo, Bradykinin, Saline, Vitamin C
Drug · Other
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
45 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 23, 2026, 10:12 AM EDT
Completed Not applicable Interventional

Diabetes Visual Function Supplement Study

NCT01646047
View directory record Official record
Conditions
Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2, Non-proliferative Diabetic Retinopathy
Interventions
multi-component nutritional supplement capsules, multi-component dietary supplement
Dietary Supplement
Lead sponsor
ZeaVision, LLC
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 22, 2015 · Synced Oct 23, 2026, 10:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

NCT00252148
View directory record Official record
Conditions
HIV Infection
Interventions
ADMVA
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
2
States / cities
New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 23, 2026, 10:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study Evaluating the Efficacy of an Ibuprofen Effervescent Tablet in the Treatment of Post-Surgical Dental Pain

NCT00631111
View directory record Official record
Conditions
Pain
Interventions
effervescent ibuprofen tablets, effervescent Aspirin plus Vitamin C tablets, ibuprofen tablets, placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
16 Years to 40 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2009 · Synced Oct 23, 2026, 10:12 AM EDT
Not listed Phase 3 Interventional

Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction

NCT04797247
View directory record Official record
Conditions
Cardiovascular Diseases, Hyper-LDL-cholesterolemia
Interventions
lerodalcibep
Drug
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 23, 2026, 10:12 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Can Post-operative TAP Block Improve Quality of Recovery After C-sections in Patients on Methadone Maintenance?

NCT01644864
View directory record Official record
Conditions
Uncontrolled Postoperative Pain
Interventions
0.375% ROPIVACAINE, placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Oct 23, 2026, 10:12 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.

NCT01197521
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
fostamatinib, placebo, fostamatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
923 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
41
States / cities
Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Oct 23, 2026, 10:12 AM EDT